Intellia Therapeutics Reports Q2 2026 Financial Results

What Happened

• On August 6, 2026, Intellia Therapeutics, Inc. (NTLA) announced its results of operations and business updates for the quarter ended June 30, 2026. The company furnished a press release covering the quarterly results as Exhibit 99.1 to a Form 8-K filed with the SEC. The Form 8-K was signed by John M. Leonard, Chief Executive Officer and President, on August 6, 2026.

Key Details

• Event date: August 6, 2026; quarter covered: ended June 30, 2026.
• Item reported: 2.02 (Results of Operations and Financial Condition) — the company announced its quarterly results.
• Exhibit provided: Press release dated August 6, 2026 furnished as Exhibit 99.1 to the Form 8-K.
• Form signed by: John M. Leonard, CEO and President.

Why It Matters

• This filing is the company’s official public notice of its quarterly earnings and business updates; investors should review the Exhibit 99.1 press release for revenue, earnings, clinical or pipeline updates, and any guidance or management commentary.
• Because the 8-K furnishes the press release, the press release is the primary source for specific financial figures and material operational developments affecting NTLA’s near-term outlook.